Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.70 |
| ▸ | NPC1 | O15118 | 7/20 | 0.70 |
| ▸ | PKM | P14618 | 3/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | PIM1 | P11309 | 1/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.59 |
| ▸ | FLT3 | P36888 | 1/20 | 0.59 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.54 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29128678 | 0.85 | RAB9A (0.66) | RAB9ANPC1PKMGAAMEN1 | |
| SCHEMBL30565139 | 0.83 | RAB9A (1.00) | RAB9ANPC1PKMGAAMEN1 | |
| SCHEMBL9750118 | 0.83 | NPC1 (0.81) | RAB9ANPC1PKMGAAMEN1 | |
| SCHEMBL519066 | 0.81 | RAB9A (0.73) | RAB9ANPC1PKMGAAMEN1 | |
| SCHEMBL3078691 | 0.81 | RAB9A (0.73) | RAB9ANPC1PKMGAAMEN1 | |
| SCHEMBL6879467 | 0.79 | RAB9A (0.70) | RAB9ANPC1PKMGAAMEN1 | |
| SCHEMBL438214 | 0.79 | RAB9A (0.70) | RAB9ANPC1PKMGAAMEN1 | |
| SCHEMBL569980 | 0.79 | RAB9A (0.70) | RAB9ANPC1PKMGAAMEN1 | |
| SCHEMBL9028468 | 0.79 | RAB9A (0.70) | RAB9ANPC1PKMGAAMEN1 | |
| SCHEMBL30578531 | 0.79 | RAB9A (0.70) | RAB9ANPC1PKMGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651643-A4 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM LLC (BM) | 2008-10-08 | — | — | EP | claimed |
| US-20070259852-A1 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM LLC | 2007-11-08 | — | — | US | claimed |
| US-7253164-B2 | Bicyclic compounds and compositions as PDF inhibitors | IRM LLC (BM) | 2007-08-07 | — | — | US | claimed |
| EP-1097927-B1 | CYANOIMINOQUINOXALINE DERIVATIVES | SHIONOGI & CO (JP) | 2006-07-19 | — | — | EP | claimed |
| EP-1651643-A2 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM, LLC (BM) | 2006-05-03 | — | — | EP | claimed |
| US-20050197326-A1 | Bicyclic compounds and compostions as PDF inhibitors | IRM LLC | 2005-09-08 | — | — | US | claimed |
| US-6903090-B2 | Such as 10-(2-ethoxyphenyl)-1,2,3,4,5,6-hexahydroazepino(4,5-b)indole; for treatment of anxiety, depression, schizophrenia, epilepsy, migraine, Alzheimers disease, sleep disorders, obesity, stress related diseases, and/or drug withdrawal | PFIZER (US) | 2005-06-07 | — | — | US | claimed |
| WO-2005011611-A2 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM, LLC (BM) | 2005-02-10 | — | — | WO | claimed |
| US-6828314-B2 | Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity | PFIZER | 2004-12-07 | — | — | US | claimed |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2003-12-04 | — | — | US | claimed |
| US-20030220321-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2003-11-27 | — | — | US | claimed |
| US-6586421-B2 | For therapy of central nervous system, including diseases, disorders, and conditions related to, such as anxiety, depression, hypertension, migraine, obesity, compulsive disorders, schizophrenia, autism, neurodegenerative disorders | PHARMACIA & UPJOHN COMPANY | 2003-07-01 | — | — | US | claimed |
| EP-1319004-A2 | SUBSTITUTED AZEPINO[4,5-B]INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-18 | — | — | EP | claimed |
| EP-1319005-A2 | SUBSTITUTED AZEPINO[4,5-B]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-18 | — | — | EP | claimed |
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | PHARMACIA & UPJOHN COMPANY | 2002-08-08 | — | — | US | claimed |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | PHARMACIA & UPJOHN COMPANY | 2002-06-20 | — | — | US | claimed |
| WO-2002024701-A2 | SUBSTITUTED AZEPINO[4,5B)INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| WO-2002024700-A2 | SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| US-20130296551-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | DAIICHI SANKYO CO LTD (JP) | 2013-11-07 | — | — | US | disclosed |
| WO-1995029907-A1 | BENZOFURAN DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107278-A1 | Substituted azepino[4,5b]indole derivatives | HTR5A, HTR1A, HTR1E | RAB9A 698/4885NPC1 1345/4885PKM 3637/4885 |
| US-20050197326-A1 | Bicyclic compounds and compostions as PDF inhibitors | PDF, FDPS, DCTPP1 | RAB9A 2389/4885NPC1 1383/4885PKM 965/4885 |
| US-20030225058-A1 | Substituted azepino[4,5b]indoline derivatives | HTR5A, HTR1A, HTR4 | RAB9A 751/4885NPC1 1176/4885PKM 3291/4885 |
| US-20130296551-A1 | 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF | CMA1, CPA3, SI | RAB9A 809/4885NPC1 175/4885PKM 2649/4885 |
| US-20070259852-A1 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | PDF, FDPS, DCTPP1 | RAB9A 1674/4885NPC1 761/4885PKM 1071/4885 |
| US-20030220321-A1 | Substituted azepino[4,5b]indole derivatives | HTR5A, HTR1A, HTR1E | RAB9A 698/4885NPC1 1345/4885PKM 3637/4885 |
| US-20020077318-A1 | Substituted azepino[4,5b] indoline derivatives | HTR5A, HTR1A, HTR4 | RAB9A 751/4885NPC1 1176/4885PKM 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.